Literature DB >> 25156254

Synergistic blockade of mitotic exit by two chemical inhibitors of the APC/C.

Katharine L Sackton1, Nevena Dimova1, Xing Zeng1, Wei Tian2, Mengmeng Zhang3, Timothy B Sackton4, Johnathan Meaders3, Kathleen L Pfaff5, Frederic Sigoillot5, Hongtao Yu6, Xuelian Luo7, Randall W King3.   

Abstract

Protein machines are multi-subunit protein complexes that orchestrate highly regulated biochemical tasks. An example is the anaphase-promoting complex/cyclosome (APC/C), a 13-subunit ubiquitin ligase that initiates the metaphase-anaphase transition and mitotic exit by targeting proteins such as securin and cyclin B1 for ubiquitin-dependent destruction by the proteasome. Because blocking mitotic exit is an effective approach for inducing tumour cell death, the APC/C represents a potential novel target for cancer therapy. APC/C activation in mitosis requires binding of Cdc20 (ref. 5), which forms a co-receptor with the APC/C to recognize substrates containing a destruction box (D-box). Here we demonstrate that we can synergistically inhibit APC/C-dependent proteolysis and mitotic exit by simultaneously disrupting two protein-protein interactions within the APC/C-Cdc20-substrate ternary complex. We identify a small molecule, called apcin (APC inhibitor), which binds to Cdc20 and competitively inhibits the ubiquitylation of D-box-containing substrates. Analysis of the crystal structure of the apcin-Cdc20 complex suggests that apcin occupies the D-box-binding pocket on the side face of the WD40-domain. The ability of apcin to block mitotic exit is synergistically amplified by co-addition of tosyl-l-arginine methyl ester, a small molecule that blocks the APC/C-Cdc20 interaction. This work suggests that simultaneous disruption of multiple, weak protein-protein interactions is an effective approach for inactivating a protein machine.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25156254      PMCID: PMC4214887          DOI: 10.1038/nature13660

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  39 in total

1.  Monitoring drug target engagement in cells and tissues using the cellular thermal shift assay.

Authors:  Daniel Martinez Molina; Rozbeh Jafari; Marina Ignatushchenko; Takahiro Seki; E Andreas Larsson; Chen Dan; Lekshmy Sreekumar; Yihai Cao; Pär Nordlund
Journal:  Science       Date:  2013-07-05       Impact factor: 47.728

Review 2.  Cubism and the cell cycle: the many faces of the APC/C.

Authors:  Jonathon Pines
Journal:  Nat Rev Mol Cell Biol       Date:  2011-06-02       Impact factor: 94.444

3.  Pharmacologic inhibition of the anaphase-promoting complex induces a spindle checkpoint-dependent mitotic arrest in the absence of spindle damage.

Authors:  Xing Zeng; Frederic Sigoillot; Shantanu Gaur; Sungwoon Choi; Kathleen L Pfaff; Dong-Chan Oh; Nathaniel Hathaway; Nevena Dimova; Gregory D Cuny; Randall W King
Journal:  Cancer Cell       Date:  2010-10-19       Impact factor: 31.743

4.  Features and development of Coot.

Authors:  P Emsley; B Lohkamp; W G Scott; K Cowtan
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2010-03-24

5.  Evidence that mitotic exit is a better cancer therapeutic target than spindle assembly.

Authors:  Hsiao-Chun Huang; Jue Shi; James D Orth; Timothy J Mitchison
Journal:  Cancer Cell       Date:  2009-10-06       Impact factor: 31.743

6.  Structures of APC/C(Cdh1) with substrates identify Cdh1 and Apc10 as the D-box co-receptor.

Authors:  Paula C A da Fonseca; Eric H Kong; Ziguo Zhang; Anne Schreiber; Mark A Williams; Edward P Morris; David Barford
Journal:  Nature       Date:  2010-11-24       Impact factor: 49.962

7.  An APC/C inhibitor stabilizes cyclin B1 by prematurely terminating ubiquitination.

Authors:  Xing Zeng; Randall W King
Journal:  Nat Chem Biol       Date:  2012-02-26       Impact factor: 15.040

8.  Substrate binding on the APC/C occurs between the coactivator Cdh1 and the processivity factor Doc1.

Authors:  Bettina A Buschhorn; Georg Petzold; Marta Galova; Prakash Dube; Claudine Kraft; Franz Herzog; Holger Stark; Jan-Michael Peters
Journal:  Nat Struct Mol Biol       Date:  2010-12-26       Impact factor: 15.369

9.  MolProbity: all-atom structure validation for macromolecular crystallography.

Authors:  Vincent B Chen; W Bryan Arendall; Jeffrey J Headd; Daniel A Keedy; Robert M Immormino; Gary J Kapral; Laura W Murray; Jane S Richardson; David C Richardson
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2009-12-21

10.  Phaser crystallographic software.

Authors:  Airlie J McCoy; Ralf W Grosse-Kunstleve; Paul D Adams; Martyn D Winn; Laurent C Storoni; Randy J Read
Journal:  J Appl Crystallogr       Date:  2007-07-13       Impact factor: 3.304

View more
  114 in total

1.  Deubiquitylase USP9X suppresses tumorigenesis by stabilizing large tumor suppressor kinase 2 (LATS2) in the Hippo pathway.

Authors:  Chu Zhu; Xinyan Ji; Haitao Zhang; Qi Zhou; Xiaolei Cao; Mei Tang; Yuan Si; Huan Yan; Li Li; Tingbo Liang; Xin-Hua Feng; Bin Zhao
Journal:  J Biol Chem       Date:  2017-11-28       Impact factor: 5.157

Review 2.  APC/C ubiquitin ligase: Functions and mechanisms in tumorigenesis.

Authors:  Morgan S Schrock; Benjamin R Stromberg; Luke Scarberry; Matthew K Summers
Journal:  Semin Cancer Biol       Date:  2020-03-09       Impact factor: 15.707

3.  NQO1 regulates mitotic progression and response to mitotic stress through modulating SIRT2 activity.

Authors:  Hong-Jun Kang; Ha Yong Song; Mohamed A Ahmed; Yang Guo; Mingming Zhang; Chuyu Chen; Massimo Cristofanilli; Dai Horiuchi; Athanassios Vassilopoulos
Journal:  Free Radic Biol Med       Date:  2018-08-13       Impact factor: 7.376

Review 4.  The role of ubiquitination in tumorigenesis and targeted drug discovery.

Authors:  Lu Deng; Tong Meng; Lei Chen; Wenyi Wei; Ping Wang
Journal:  Signal Transduct Target Ther       Date:  2020-02-29

Review 5.  Targeting Cdc20 as a novel cancer therapeutic strategy.

Authors:  Lixia Wang; Jinfang Zhang; Lixin Wan; Xiuxia Zhou; Zhiwei Wang; Wenyi Wei
Journal:  Pharmacol Ther       Date:  2015-04-04       Impact factor: 12.310

6.  A novel function of anaphase promoting complex subunit 10 in tumor progression in non-small cell lung cancer.

Authors:  Yanan Wang; Tianyu Han; Mingxi Gan; Meng Guo; Caifeng Xie; Jiangbo Jin; Song Zhang; Pengcheng Wang; Jiaqing Cao; Jian-Bin Wang
Journal:  Cell Cycle       Date:  2019-04-25       Impact factor: 4.534

7.  Diosgenin exerts its tumor suppressive function via inhibition of Cdc20 in osteosarcoma cells.

Authors:  Cheng Long; Juan Chen; Hua Zhou; Tao Jiang; Xiang Fang; Dong Hou; Ping Liu; Hong Duan
Journal:  Cell Cycle       Date:  2019-01-22       Impact factor: 4.534

Review 8.  Clinically Applicable Inhibitors Impacting Genome Stability.

Authors:  Anu Prakash; Juan F Garcia-Moreno; James A L Brown; Emer Bourke
Journal:  Molecules       Date:  2018-05-13       Impact factor: 4.411

Review 9.  Targeting the ubiquitin pathway for cancer treatment.

Authors:  Jia Liu; Shavali Shaik; Xiangpeng Dai; Qiong Wu; Xiuxia Zhou; Zhiwei Wang; Wenyi Wei
Journal:  Biochim Biophys Acta       Date:  2014-12-04

10.  Nuclear pore protein NUP88 activates anaphase-promoting complex to promote aneuploidy.

Authors:  Ryan M Naylor; Karthik B Jeganathan; Xiuqi Cao; Jan M van Deursen
Journal:  J Clin Invest       Date:  2016-01-05       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.